



## Genomic Instability and How to Exploit It for Cancer Cell Vulnerability

Guest Editor:

**Dr. Samirkumar B. Amin**

The Jackson Laboratory for  
Genomic Medicine, Farmington,  
CT, USA

samir.amin@jax.org

Deadline for manuscript  
submissions:


**closed (22 September 2022)**

### Message from the Guest Editor

**Genomic Instability** is a major source of both variation required for the clonal evolution of cancer and the resulting intratumoral heterogeneity (ITH). This in turn drives tumor growth and acts as a significant barrier to effective cancer therapies.

In this Special Issue, we invite original research articles and reviews related to some of the prevailing questions regarding genomic instability in cancer: How do cancer cells develop tolerance to damage insinuated by progressive instability? Which genes and regulatory regions within SCNAs and aneuploidies enable this tolerance and promote cancer cell fitness? Which stress-response barriers in the natural history of tumor evolution cancer cells must overcome by selecting for fitness-promoting SCNAs and aneuploid regions? Which structural alterations are a result of selective pressures induced by either the tumor immune microenvironment or cancer therapies (i.e., to identify the SCNAs driving recurrent or treatment-resistant metastatic cancers)?





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and other databases.

**Journal Rank:** [JCR - Q1 \(Oncology\)](#) / [CiteScore - Q2 \(Oncology\)](#)

## Contact Us

---

*Cancers*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)